Endacea Dx

Commercialize a diagnostic for sepsis and satisfy a major medical need.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Raleigh, NC, USA
  • Currency USD
  • Founded March 2012
  • Employees 0
  • Website endacea.com

Company Summary

Endacea Dx was spun off in order to commercialize Endacea's patented diagnostic that will detect endotoxin in the blood of patients who have or will soon have sepsis. This is a response to a great medical need. (Parent company also has therapeutic for sepsis under development and close to clinical trials.)

Team

  • 0 0

  • Constance Neely Wilson
    CEO, Founder and Chief Scientific Officer

    Constance Neely Wilson, M.D., Endacea’s CEO, Founder and Chief Scientific Officer, is the inventor of Endacea's A1 AR based technologies. She is a critical care physician scientist with strong expertise in cardiopulmonary medicine as a result of her fellowships at Massachusetts General Hospital in respiratory intensive care, pulmonary, and cardiology medicine and her practice of medicine for 21 years. She is an adenosine receptor pharmacologist a

  • Jeff Scribner

Advisors

  • Outside counsel are engaged for patent and other purposes.
    Lawyer
    Unconfirmed
    Endacea Dx will use accountants retained by parent company.
    Accountant
    Unconfirmed

Previous Investors

  • At the moment, one outside investor in Endacea Dx $200K
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free